Remodulin

Report
15 Pages
October 2018
Region: Global
Citeline
ID: 4775235

Drug Overview
Remodulin (United Therapeutics/Mochida) contains treprostinil, which is a prostaglandin analog that functions as a prostaglandin I2 receptor agonist. This leads to potent vasodilation of the pulmonary arteries and inhibition of platelet aggregation.

Analyst Outlook
Remodulin (treprostinil; United Therapeutics/Mochida) is a last-line treatment option for more severe patients. Despite Remodulin’s subcutaneous formulation reducing the risk of severe sepsis and thromboembolism associated with other intravenously administered prostacyclin analogs, injection site pain and site reactions remain a barrier to the drug’s uptake. Accordingly, United Therapeutics is developing three new formulations of Remodulin to overcome administration difficulties. The complexity of Remodulin’s administration and the introduction of a novel implantable pump developed in collaboration with Medtronic may provide a sustained market for Remodulin despite facing generic competition from 2018. Furthermore, United Therapeutics’ defensive acquisition of SteadyMed has enabled the company to circumvent potential competition from SteadyMed’s pipeline asset Trevyent, which is a PatchPump with treprostinil for subcutaneous treatment of pulmonary arterial hypertension (PAH).

OVERVIEW

Drug Overview
Product Profiles
Remodulin : Pulmonary hypertension

LIST OF FIGURES

Figure 1: Remodulin for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 3: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 4: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country, 2016–25

LIST OF TABLES

Table 1: Remodulin drug profile
Table 2: Remodulin pivotal trial data in pulmonary hypertension
Table 3: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9700EUR$10,000USD£8,309GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47528EUR$49,000USD£40,712GBP

Table of Contents

Related Topics

Related Reports

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Global Market Report 2024

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Global Pulmonary Arterial Hypertension Market by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5), Distribution (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030